Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Blopress, Takepron to Go to Teva-Takeda Joint Venture
January 5, 2016
- Torii Files NDA for Allergen Immunotherapy Tablet for Cedar Pollinosis
January 5, 2016
- ASKA Files Rifaximin for Hepatic Encephalopathy
December 25, 2015
- Bristol-Myers Files Elotuzumab for Relapsed, Refractory Multiple Myeloma in Japan
December 25, 2015
- FDA OKs Selexipag Originated by Nippon Shinyaku
December 24, 2015
- MSD Seeks Japan Approval for Pembrolizumab for Melanoma
December 24, 2015
- Israel’s Pluristem Therapeutics to Enter into Japanese Regenerative Medicine Market
December 24, 2015
- Lacosamide Reduces Partial-Onset Seizures in PIII: Daiichi Sankyo, UCB
December 22, 2015
- Shionogi, Mundipharma Seal Agreement on Ethical Isodine Products
December 22, 2015
- CSL Behring Files rIX-FP for Hemophilia B Treatment in Japan
December 22, 2015
- PeptiDream Ties Up with Genentech for Peptide Discovery
December 22, 2015
- Eisai to Transfer Manufacturing Subsidiary to Alfresa
December 21, 2015
- 80% Target for Generics Presents “Business Opportunity” for Alfresa Fine Chemical: Pres. Miyadera
December 21, 2015
- Acucela Establishes Japanese Subsidiary to Strengthen Business in Japan
December 21, 2015
- BMKK, Ono Initiate Multinational PIIIb Study of Orencia in Japan
December 21, 2015
- Ohara Files Japan NDA for ALL Drug Crisantaspase
December 18, 2015
- Taiho, Meiji Seika Pharma to Comarket Allergy Drug
December 18, 2015
- AbbVie Files Viekirax for Genotype 2 Hepatitis C
December 18, 2015
- Opdivo Gets Lung Cancer Indication in Japan: Ono
December 18, 2015
- Takeda to Divest Respiratory Biz to AstraZeneca
December 17, 2015
ページ
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…